Evidence map›Paper›PMID 34309124›Full record

Trial reportJournal of genetic counseling2022

Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression.

Talia S Schwartz, Kurt D Christensen, Melissa K Uveges, Susan E Waisbren, Amy L McGuire, Stacey Pereira, Jill O Robinson, Alan H Beggs, Robert C Green, BabySeq Project Team and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of genetic counseling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genomic newborn screening for rare diseases.Nature reviews. Genetics · 2023
    Review
  9. Dispatches from Biotech beginning BeginNGS: Rapid newborn genome sequencing to end the diagnostic and therapeutic odyssey.American journal of medical genetics. Part C, Seminars in medical genetics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Talia S SchwartzDivision of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-5339-4451
Kurt D ChristensenPRecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.ORCID 0000-0003-4068-776X
Melissa K UvegesDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-0251-4393
Susan E WaisbrenDivision of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-0013-700X
Amy L McGuireCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-7819-519X
Stacey PereiraCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-6541-3904
Jill O RobinsonCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-0487-304X
Alan H BeggsDivision of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-8818-0568
Robert C GreenThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
BabySeq Project Team
Gloria A BachmannRutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.ORCID 0000-0002-0404-2123
Arnold B RabsonRutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.ORCID 0000-0001-5651-2521
Ingrid A HolmDivision of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-4712-8821

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
Genome Sequence-Based Screening for Childhood Risk and Newborn IllnessU19HD077671 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI BEGGS, ALAN H., GREEN, ROBERT C. · 2013 to 2018
$6.1M
Precision Medicine Policy and Treatment (PreEMPT) Model IIR01HD090019 · NICHD · HARVARD PILGRIM HEALTH CARE, INC. · PI Kurt Derek Christensen · 2017 to 2026
$5.7M
Cost-effectiveness of Whole Genome Sequencing of Healthy AdultsK01HG009173 · NHGRI · HARVARD PILGRIM HEALTH CARE, INC. · PI CHRISTENSEN, KURT DEREK · 2016 to 2020
$626k
NHGRI NIH HHS K01 HG009173NICHD NIH HHS P50 HD105351NICHD NIH HHS R01 HD090019NICHD NIH HHS U19 HD077671NIH HHS K01HG009173 : R01-HD090019NIH HHS U19HD077671
6 · The paper itself

Abstract

Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents' depressive symptoms were associated with their child's participation in a randomized-controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post-disclosure, and 3 months post-disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow-up conversations were coded for themes. Forty-five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post-disclosure and another 1.1 points 3 months post-disclosure (both p ≤ .014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post-disclosure, and decreased by 3.8 points at 3 months post-disclosure (both p < .001). Nine parents scored above thresholds only at 3 months post-disclosure after increasing an average of 5.7 points from immediately post-disclosure (p < .001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.

Indexed as

Depression, PostpartumMajor Depressive DisorderChildDepressionFemaleGenomicsHumansInfant, NewbornMothersParentsexome sequencingmental healthnewborn screeningparentspediatricspsychosocial

Identifiers

PMID34309124
PMCPMC8789951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.